Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

co.don® AG - Application filed for EU-wide approval for the articular cartilage product chondrosphere®


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-01-08 11:55:36 -

co.don AG /
co.don® AG - Application filed for EU-wide approval for the articular cartilage 
product chondrosphere® 
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

Teltow, 08. January 2013

co.don®  AG has submitted its application for EU marketing authorisation for the
articular  cartilage  product  chondrosphere®  to  the relevant committee of the
European Medicines Agency in London.

The official approval procedure began on 26.12.2012.

A European regulation stipulates that tissue products derived from biotechnology
processes,  which include the tissue transplants from co.don AG, require central
marketing authorisation from the European Commission.

Now that co.don® AG has filed the extensive approval documentation by the end of
2012, in  line with its own internal timetable, 
the European Medicines Agency is responsible for carrying out the scientific evaluation of the application and making a recommendation on marketing authorisation to the European Commission. The product can still be sold in Germany, the main sales market for co.don® AG, as the company applied for the appropriate approval from the national German federal authority before the deadline. At the same time co.don® AG is intensifying its marketing and sales activities in non-EU member states both inside and outside Europe. About co.don® AG: The company is based in Teltow, Brandenburg, and was founded in 1993. Since 2001 the biopharmaceutical specialist has been listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). co.don AG(®) uses tissue engineering - the cultivation and growth of autologous tissue cells - to develop innovative products and therapeutic concepts for the orthopaedic and neurosurgical markets. The cell-based biological drugs (autologous cell transplants for articular cartilage and intervertebral disks) are produced without the use of antibiotics, growth factors and genetic engineering. The Executive Board of co.don(®) AG is made up of Dr Andreas Baltrusch (CEO) and Vilma Methner (COO, CSO). Further information is also available from: www.codon.de Press contact BrunoMedia GmbH R.-D. Brunowsky Telephone:  01704621440 Email: brunowsky@brunomedia.de Press release (PDF): hugin.info/132731/R/1668926/542136.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: co.don AG via Thomson Reuters ONE [HUG#1668926]


Press Information:




Contact Person:


Disclaimer: © 2013 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser